RAPT Stock Up 59% after 10-Day Win Streak
RAPT Therapeutics (RAPT) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 59% return. The company has gained about $288 Mil in value over the last 10 days, with its current market capitalization at about $485 Mil. The stock remains 42.4% above its value at the end of 2024. This compares with year-to-date returns of 12.2% for the S&P 500.
RAPT provides oral small molecule therapies targeting oncology and inflammatory diseases, with a lead drug candidate that selectively inhibits type 2 T helper cell migration to inflamed tissues. After this rally, is RAPT still a buy – or is it time to lock in gains? Deep dive with Buy or Sell RAPT.
Comparing RAPT Stock Returns With The S&P 500
The following table summarizes the return for RAPT stock vs. the S&P 500 index over different periods, including the current streak:
- Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy?
- OKE Looks Smarter Buy Than Pembina Pipeline Stock
- UI Looks Smarter Buy Than Cisco Systems Stock
- Better Value & Growth: AU Leads Alamos Gold Stock
- 5 Catalysts To Monitor Over In The Next 2 Quarters For AMZN Stock
- Corning Stock To $126?
| Return Period | RAPT | S&P 500 |
|---|---|---|
| 1D | 2.1% | -0.1% |
| 10D (Current Streak) | 59.3% | 2.4% |
| 1M (21D) | 53.5% | 2.3% |
| 3M (63D) | 129.6% | 10.3% |
| YTD 2025 | 42.4% | 12.2% |
| 2024 | -93.6% | 23.3% |
| 2023 | 25.5% | 24.2% |
| 2022 | -46.1% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 33 S&P constituents with 3 days or more of consecutive gains and 60 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 22 | 14 |
| 4D | 1 | 42 |
| 5D | 2 | 1 |
| 6D | 3 | 0 |
| 7D or more | 5 | 3 |
| Total >=3 D | 33 | 60 |
Key Financials for RAPT Therapeutics (RAPT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-127.1 Mil | $-136.1 Mil |
| Net Income | $-116.8 Mil | $-129.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-19.3 Mil | $-19.5 Mil |
| Net Income | $-17.2 Mil | $-17.6 Mil |
While RAPT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.